Every 8-K that Shoulder Innovations, Inc. (SI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SI filings page.
Shoulder Innovations, Inc., a commercial-stage medical technology company focused on the shoulder surgical care market, has promoted Jon Osborne to Chief Commercial Officer, effective August 6, 2026. He previously served as Vice President of Commercial Development and will now oversee all elements of the company’s commercial organization.
Osborne will work closely with the Customer Experience and Medical Education team to execute the company’s commercial strategy, emphasizing scaling the organization, deepening surgeon and partner relationships, and aligning commercial execution with the company’s innovation efforts. The company highlights his extensive orthopedic industry background and prior leadership roles at Smith & Nephew and other medical device firms.
Shoulder Innovations reported strong second quarter 2026 results, with net revenue of $17.2 million, a 56% increase over the prior-year quarter, and gross margin expanding to 78.3% from 76.2%. Growth was driven by higher implant volumes, more customers and a higher average selling price of $7,674.
The company sold 2,238 implant systems, about 50% more than a year earlier, but continued to invest heavily, lifting selling, general and administrative expenses to $20.1 million and research and development to $3.4 million. Operating loss widened to $10.0 million, while net loss narrowed to $10.2 million and Adjusted EBITDA loss to $8.0 million.
Shoulder Innovations closed two new credit facilities totaling up to $50 million and ended June 30, 2026 with $99.0 million in cash, cash equivalents and marketable securities. On this basis it raised full-year 2026 net revenue guidance to $67–69 million, implying about 42–46% growth over 2025.
Shoulder Innovations entered a new Loan and Security Agreement with Stifel Bank that provides up to $50 million of senior secured financing. It includes a fully funded $15 million growth capital term loan and a $30 million asset-based revolving line of credit, with an additional $5 million available subject to conditions.
The term loan proceeds were used to repay and terminate the prior Trinity Capital facility, including $15.7 million of principal, interest and premiums, releasing Trinity’s security interests. The new term loan bears interest at the greater of 0.75% below prime or 5.00%, is interest-only through June 30, 2029, and matures in June 2031.
The revolving facility, which was undrawn at closing, bears interest at the greater of the prime rate or 5.00%, matures in June 2029, and is secured by substantially all company assets other than specified intellectual property. The agreement includes customary covenants and a springing minimum revenue test tied to total debt and liquidity.
Shoulder Innovations, Inc. reported the results of its 2026 Annual Meeting of Stockholders, where a quorum of 16,424,584 common shares was present virtually or by proxy. Each share had one vote.
Stockholders elected two Class I directors. Robert Ball received 10,576,791 votes for and 4,236,696 votes withheld, with 1,611,097 broker non-votes. Andrew Hykes received 14,812,410 votes for and 1,077 votes withheld, plus 1,611,097 broker non-votes. Both will serve three-year terms until the 2029 Annual Meeting, subject to earlier death, resignation, or removal.
Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 16,415,933 votes for, 2 votes against, and 8,649 abstentions, and no broker non-votes.
Shoulder Innovations reported strong first quarter 2026 growth but wider losses. Net revenue rose 65% to $16.7 million, driven by higher implant volumes and more customers, and gross margin improved to 77.7% from 76.9%.
Selling, general and administrative expenses increased 73% to $18.2 million and research and development expenses rose 137% to $3.8 million, reflecting commercial expansion and product development. This led to an operating loss of $9.0 million and net loss of $8.4 million, both roughly double the prior-year period. Adjusted EBITDA loss was $7.0 million.
Management raised full-year 2026 net revenue guidance to a range of $65 million to $68 million, implying approximately 37% to 44% growth over 2025. The company ended March 31, 2026 with $108.5 million in cash, cash equivalents and marketable securities, providing resources to support its growth strategy.
Shoulder Innovations, Inc. announced the full commercial launch of its InSet™ I-135RFX Humeral Stem, expanding its I-Series shoulder implant portfolio. This launch follows a successful limited market release and FDA 510(k) clearance for additional fracture indications.
The InSet™ I-135RFX can now be used in primary, revision, and fracture total shoulder arthroplasty procedures, in both anatomic and reverse configurations. It joins the InSet™ 95 and InSet™ 70, launched in 2024 and 2025, and is built on the company’s lateral-lateral implant philosophy aimed at reducing complications and improving post-operative range of motion.
Shoulder Innovations, Inc. entered into a new long-term lease for a purpose-built corporate headquarters. The company agreed with Ventura Office Park Lot #8, LLC to have a roughly 15,200-square-foot office and warehouse building constructed in Byron Center, Michigan.
The lease runs for an initial 10-year term, with two additional five-year extension options and certain expansion rights. Estimated aggregate rent over the initial term is about $4.4 million. The company has paid a $33.0 thousand security deposit and a further $0.5 million down payment toward construction costs. Possession is expected around the fourth quarter of 2027, after a certificate of occupancy is issued and the landlord substantially completes its work.
Shoulder Innovations reported strong growth but widening losses for the fourth quarter and full year 2025, and announced that director Michael Carusi will not stand for re-election at the 2026 annual meeting, a decision the company says is not due to any disagreement with management or the board.
Fourth quarter net revenue rose 65% to $14.4 million, while full-year net revenue increased 50% to $47.3 million, driven by higher implant system volumes and new customers. Gross margin remained high at about 77% for both the quarter and the year, reflecting attractive product economics.
Despite this growth, operating expenses climbed sharply, leading to a 2025 operating loss of $26.3 million and a net loss of $40.4 million. The company ended 2025 with $124.3 million in cash, cash equivalents and marketable securities, and issued 2026 net revenue guidance of $62 million to $65 million, implying growth of roughly 31% to 37% over 2025.
Shoulder Innovations, Inc. reported that on February 26, 2026, Geoff Pardo resigned as a Class I director, a member of the Compensation Committee, and Chair of the Nominating and Corporate Governance Committee, effective immediately. The company stated his resignation was not due to any disagreement with management or the Board.
On the same date, the Board appointed Andrew (Drew) Hykes, age 53, as a Class I director and member of the Compensation Committee, also effective immediately. He will receive standard non-employee director compensation and enter into the company’s standard indemnification agreement. The Board determined he is an independent director and meets New York Stock Exchange and Exchange Act requirements for Compensation Committee service.
The filing and accompanying press release highlight Mr. Hykes’s more than 25 years of medical device and healthcare experience, including leadership roles at Okami Medical, Inari Medical, Sequent Medical, and Medtronic, as well as his banking background and business degrees from the University of Wisconsin–Madison and Harvard Business School.
Shoulder Innovations, Inc. reported that it has entered into a strategic partnership with Interventional Systems to bring a robotic platform to shoulder arthroplasty procedures. The collaboration aims to pair Shoulder Innovations’ implant and surgical know-how with Interventional Systems’ robotics technology to support more precise shoulder replacement surgery. The news was shared through a press release furnished under a current report, meaning it provides an operational and strategic update rather than new financial results.
Shoulder Innovations (SI) filed an 8‑K reporting its quarterly results disclosure. The company announced that it issued a press release with financial results for the quarter ended September 30, 2025 and hosted a conference call on November 11, 2025 to discuss those results and full‑year 2025 guidance.
The press release is furnished as Exhibit 99.1 and the call transcript as Exhibit 99.2. The materials are being furnished, not filed, under the Exchange Act and are not subject to Section 18 liabilities, nor incorporated by reference unless specifically referenced.
Shoulder Innovations, Inc. filed a current report to share that it has released its financial results for the quarter ended June 30, 2025. On September 9, 2025, the company issued a press release with these results, which is furnished as Exhibit 99.1.
The company notes that the press release and related information are being furnished rather than filed, meaning they are not subject to certain liability provisions of the Exchange Act and are not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.